Alveolar Soft-part Sarcoma Clinical Trial
— CASPSOfficial title:
A Phase II Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)
| Verified date | January 2019 |
| Source | Institute of Cancer Research, United Kingdom |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The study is a two-arm, randomised, double-blind, international, multi-centre phase II trial
of cediranib in Alveolar Soft Part Sarcoma (ASPS).
The study aims to confirm the ability of cediranib to halt disease progression in patients
with metastatic ASPS, as measured by the change in tumour size at 24 weeks after
randomisation, and to produce objective response according to RECIST criteria.
| Status | Active, not recruiting |
| Enrollment | 36 |
| Est. completion date | January 2020 |
| Est. primary completion date | July 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 16 Years and older |
| Eligibility |
Inclusion Criteria: 1. Histologically confirmed diagnosis of ASPS (central confirmation not required at study entry) 2. Age 16 years and older 3. Availability of archived tissue blocks or unstained slides to enable confirmation of t(X;17) translocation 4. ECOG Performance Status of 0-1 5. Life expectancy of >12 weeks 6. Progressive disease as defined by RECIST v1.1 within 6 months prior to randomisation 7. Measurable metastatic disease using RECISTv1.1, i.e. at least one lesion 10 mm in diameter (15 mm in short axis for nodal lesions) assessable by CT (or MRI for brain metastases). 8. Patients with brain metastases are permitted provided disease is controlled with a stable dose of corticosteroid and/or non-enzyme inducing anticonvulsant 9. The capacity to understand the patient information sheet and ability to provide written informed consent 10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures 11. Able to swallow and retain oral medication Exclusion Criteria: 1. Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count =1.5 x 109/L or platelet count =100 x 109/L 2. Serum bilirubin = 1.5 x ULN (unless Gilbert's syndrome) 3. ALT or AST = 2.5 x ULN. If liver metastases are present, ALT or AST > 5 x ULN 4. Serum creatinine > 1.5 x ULN or a creatinine clearance (calculated or measured) of = 50mL/min 5. Greater than +1 proteinuria unless urinary protein < 1.5g in a 24 hr period or protein/creatinine ratio < 1.5. 6. History of significant gastrointestinal impairment, as judged by the Investigator, that would significantly affect the absorption of cediranib. 7. Patients with a history of poorly controlled hypertension with resting blood pressure >150/100 mmHg in the presence or absence of a stable regimen of anti-hypertensive therapy. 8. Any evidence of severe or uncontrolled co-morbidities e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease, or active and uncontrolled infection. 9. Evidence of prolonged QTc >480 msec (using Bazetts correction, for which the formula is: QTc = QT/vRR) or history of familial long QT syndrome. 10. Significant recent haemorrhage (>30mL bleeding/episode in previous 3 months) or haemoptysis (>5mL fresh blood in previous 4 weeks). 11. Major thoracic or abdominal surgery in the 14 days prior to entry into the study, or a surgical incision that is not fully healed. 12. Pregnant or breast-feeding women; women of childbearing potential with a positive pregnancy test prior to receiving study medication; women the intention of pregnancy during study treatment; women of child bearing potential unwilling to have a urine or serum pregnancy test prior to study entry (even if surgically sterilised). 13. Men and women of childbearing potential unwilling to use adequate birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilisation) for the duration of the study and should continue such precautions for 2 weeks after receiving the last study treatment. 14. History of anticancer (including investigational, non-registered) treatment in the four weeks prior to first dose of cediranib, with the exception of palliative radiotherapy for symptom control. 15. Previous treatment with cediranib. 16. Known hypersensitivity to any excipient of cediranib. 17. History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within 5 years, unless the patient has been disease free for 2 years and there is a tissue diagnosis of the primary cancer of interest from a target lesion. 18. Other concomitant anti-cancer therapy (including LHRH agonists) except steroids 19. Recent history of thrombosis 20. Patients with brain metastases if they are symptomatic requiring increasing steroids in the previous six weeks to study entry or those with evidence of recent and/or active bleeding, or those causing uncontrolled seizures. |
| Country | Name | City | State |
|---|---|---|---|
| Australia | Princess Alexandra Hospital | Brisbane | |
| Australia | Royal Prince Alfred Hospital | Sydney | |
| Spain | Hospital Santa Cruz i Sant Pau | Barcelona | |
| Spain | Hospital Puerta de Hierro | Madrid | |
| Spain | Hospital Miguel Servet | Zaragoza | |
| United Kingdom | Bristol Haematology and Oncology Centre | Bristol | |
| United Kingdom | Royal Marsden Hospital | London | |
| United Kingdom | University College London Hospital | London | |
| United Kingdom | Christie Hospital | Manchester | |
| United Kingdom | Royal Victoria Infirmary/Freeman Hospital | Newcastle-Upon-Tyne | |
| United Kingdom | Nottingham University Hospitals | Nottingham |
| Lead Sponsor | Collaborator |
|---|---|
| Institute of Cancer Research, United Kingdom | Royal Marsden NHS Foundation Trust |
Australia, Spain, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To evaluate the efficacy of cediranib in the treatment of ASPS by measuring the percentage change in the sum of target marker lesion diameters from randomisation to week 24 (or progression if sooner) compared to treatment with placebo. | 24 Weeks of treatment | ||
| Secondary | Response rate at week 24, best response using RECISTv1.1 and best reduction (%) in tumour size | 24 Weeks of treatment | ||
| Secondary | Progression-free survival and percentage alive and progression-free at 12 months (APF12) | 12 months of treatment | ||
| Secondary | Length of Overall survival | Patients will be followed up every 12 weeks | ||
| Secondary | The safety and tolerability profile of cediranib in patients with ASPS | Assessments will be made at every study visit (8-12 weekly) |